

Your Dollars At Work

In January, the Food and Drug Administration (FDA) approved ibrutinib to treat patients with Waldenstrom's macroglobulinemia (WM), a rare form of lymphoma.

This approval marks the first therapy indicated specifically for WM and offers new hope for these patients. While numerous therapies have been used to treat WM, until now there was no standard of care for the disease and the treatments were not curative.

LLS supported research that led to the development of this drug and is committed to developing additional therapies for WM, by funding studies at the Dana-Farber Cancer Institute, where new therapeutic targets to control WM are being explored.

someday is today®

The FDA has granted Fast Track designation for CPX-351 for the treatment of elderly patients with secondary acute myeloid leukemia (AML).

The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions which demonstrate the potential to address unmet medical needs. The FDA designation makes it likely that if the therapy performs well in the later phase clinical trials, it will be made available to patients more quickly. Under the Fast Track designation, Celator Pharmaceuticals, the company developing this therapy, will be able to:

- Communicate more frequently with the FDA throughout the development and review process;
- Submit sections of its application on a rolling basis; and
- Be eligible for accelerated approval and review if the clinical data holds strong.

A Phase III trial is now underway that will compare CPX-351 with the standard of care in patients aged 60 to 75 years.

To date, LLS has invested \$4 million into this partnership, with another \$5 million committed to complete the clinical trials.

LLS Honored Hero Andrew Christianson



Andrew and his mom, Mardith, at the Student of the Year Grand Finale Gala

In September 2011, Andrew was an active, healthy 11 year-old. Shortly thereafter, he began suffering from headaches, exhaustion, fevers, and a bloody nose. Although his parents suspected the common flu or an upper respiratory infection, initial tests were inconclusive. When his temperature reached 105°F, Andrew's parents rushed him to Walter Reed National Military Medical Center where doctors delivered the devastating news that Andrew had acute lymphoblastic leukemia (ALL).

Tests revealed that Andrew's bone marrow was 95% cancerous. Immediate, aggressive treatment was critical. Over the next 13 months, Andrew endured a grueling treatment regimen, including two bone marrow biopsies, heavy doses of chemotherapy, 17 lumbar punctures, and four extended hospital stays.

In October 2012, Andrew began his maintenance therapy, which consisted of three oral chemotherapy drugs daily and quarterly lumbar punctures. While the treatment he received saved his life, it has not been without side effects. Toxic chemotherapy drugs damaged Andrew's liver and heavy doses of steroids resulted in Andrew developing osteonecrosis in his knees, requiring additional treatment and the use of crutches. Fortunately, the treatment was successful and Andrew's bones healed.

In January 2015, Andrew completed the maintenance phase of his treatment! He is back to swimming competitively and is excelling in honors classes at school.

"We are grateful to LLS for the support and information they have provided to Andrew and our family."

Mardith, Andrew's mom

Andrew served as the Honored Hero for the 2015 Student of the Year campaign, inspiring 12 high school student candidate teams to raise more than \$401,000 in just six weeks.

Companies That Make An Impact

MorganFranklin Consulting

Founded in 1998 by Bob Morgan, Rob Franklin, and Ron Morgan, MorganFranklin Consulting has a long-standing tradition of strengthening the Washington, D.C. communities in which its employees live and work.

As a steadfast supporter of The Leukemia & Lymphoma Society (LLS), MorganFranklin and its senior leadership team & more than 250 employees have made a tremendous impact on reaching our goal of a world without blood cancers.

C.E. Andrews, MorganFranklin's Chief Executive Officer since 2013, has been a champion of the LLS mission for more than 20 years, supporting LLS at the highest levels. As Co-Chair of the Leukemia Ball in 2000 and Chair in 2001, he helped lay the foundation for the event to become one of the largest non-political black-tie events in Washington, D.C. In 2012 alone, C.E. chaired an individual giving campaign that raised more than \$270,000 for LLS.

C.E. currently serves as Chair of a local initiative to raise \$1 million to fund the LLS partnership with Celator Pharmaceuticals and accelerate the most promising new treatment for acute myeloid leukemia (AML) from clinical trials into patients' hands. To date, C.E. has been instrumental in raising \$794,000 toward that goal to advance what could be the first successful new treatment for AML in more than 30 years. As an ambassador for LLS, he continues to open doors to new volunteers & supporters and empower those around him to engage in leadership roles.

"It has been a great honor to work with LLS over the years, and I am proud to be part of a company that shares this long history of supporting the mission. Twenty years ago, when I first became involved with LLS, the progress achieved today would have been unheard of in the fight against blood cancers. Today, through the support of countless individuals, researchers, and patients teaming with LLS to find cures, we are closing in on the promise of a world without blood cancers. We will get there."

C.E. Andrews, CEO, MorganFranklin Consulting

In addition, Jeana Foster, Senior Manager of Events and Corporate Social Responsibility at MorganFranklin, was named the 2013 LLS National Capital Area Chapter "Woman of the Year," raising nearly \$170,000 for the LLS mission. Jeana continues to serve on the Man & Woman of the Year Leadership Team, recruiting and mentoring candidates to success.

And where MorganFranklin's employees are engaged and passionate, they have the full support of the company. MorganFranklin has sponsored the Man & Woman of the Year and Light The Night campaigns to encourage participants to reach their maximum potential. For the past eight years, MorganFranklin employees have formed Light The Night teams, raising more than \$40,000 in the process.

"We are grateful to call MorganFranklin a partner and friend in our quest for cures. The generosity and dedication shown by the firm's executives and employees are the driving forces behind some of LLS's greatest achievements."

Beth Gorman, Executive Director, NCA Chapter

MORGANFRANKLIN®

CONSULTING

Mark Your Calendar

Blood Cancer Conference

Saturday, May 9th
9:00 AM - 4:00 PM

Northern Virginia Community College
Annandale, VA

This free, full-day conference is aimed at reaching cancer patients and their families to help build a community of support and offer educational information on relevant topics. To register, please contact Sara.Rudolph@lls.org or 703.399.2940.

The Ryan Kerrigan Leukemia Golf Classic

Join Ryan Kerrigan, his teammates, and coaches for



Monday, May 11th
The Golf Club at Lansdowne
Leesburg, VA

For more information on sponsorship opportunities, please contact Mary.Angelo@lls.org or 703.399.2906.

Team In Training Block Party

Saturday, May 16th
1:00 PM - 4:00 PM
Road Runner Sports
Falls Church, VA

Join our coaches, mentors, and honorees at the official start to the Fall TNT season and meet the TEAM! Take part in a scavenger hunt run, or simply enjoy the food, music, and beverages provided by Road Runner Sports. For more information, please contact Jenny.DeMarco@lls.org or 703.399.2908.

Interested in finding out more about upcoming events, volunteer opportunities, patient services, education programs, giving opportunities, or advances in research? Visit lls.org/nca or follow @LLSNatCap on Facebook, Twitter, and Instagram.

Ways to Support LLS

Include LLS in your Giving Plans

If you would like to include LLS in your will or trust, please use the following language: *I give to The Leukemia & Lymphoma Society [1311 Mamaroneck Avenue, White Plains, NY 10605] \$_____ (specific dollar amount or percentage of my estate or specified asset).*

Workplace Giving Opportunities

LLS participates in several workplace giving campaigns including CHC, CFC, and the United Way. To designate LLS, use **CHC/CFC code 72322** or write in "LLS" for United Way.

The National Capital Area Chapter of The Leukemia & Lymphoma Society
3601 Eisenhower Avenue, Suite 450, Alexandria, VA 22304 — 703.399.2900 — www.lls.org/nca